Arcus Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RCUS$18.95+3.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In millions, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| License and development service revenue(Includes $75, $74 and $330 from a related party) | $80 | $74 | $345 |
| Other collaboration revenue(Includes $37, $33 and $31 from a related party) | 37 | 38 | 38 |
| Total revenues | 117 | 112 | 383 |
| Operating expenses: | |||
| Research and development(Net of recoveries of $110, $132 and $25 from a related party) | 340 | 288 | 257 |
| General and administrative(Net of recoveries of $—, $1 and $— from a related party) | 117 | 104 | 72 |
| Total operating expenses | 457 | 392 | 329 |
| Income (loss) from operations | (340) | (280) | 54 |
| Non-operating income (expense): | |||
| Interest and other income, net | 41 | 16 | 1 |
| Effective interest on liability for sale of future royalties | (2) | (2) | — |
| Total non-operating income, net | 39 | 14 | 1 |
| Income (loss) before income taxes | (301) | (266) | 55 |
| Income tax expense | (6) | (1) | (2) |
| Net income (loss) | $(307) | $(267) | $53 |
| Net income (loss) per share: | |||
| Basic | $(4.15) | $(3.71) | $0.76 |
| Diluted | $(4.15) | $(3.71) | $0.71 |
| Shares used to compute net income (loss) per share: | |||
| Basic | 74.0 | 72.0 | 69.3 |
| Diluted | 74.0 | 72.0 | 74.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.